Smoking cessation in patients with respiratory diseases: A high priority, integral component of therapy

European Respiratory Journal

Volumn 29, Issue 2, 2007, Pages 390-417

  Tønnesen, Philip ^a   Carrozzi, L ^b   Fagerstrom K O ^f   Gratziou, C ^g   Jimenez Ruiz, C ^h   Nardini, S ^d   Viegi, G ^c   Lazzaro, C ^e   Campell, I A ⁱ   Dagli, E ^k   West, R ^j  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d Smoking Cessation Clinic   (Italy)

^e Economic Evaluation of Health Care Programmes   (Italy)

^f Smoker's Information Centre   (Sweden)

^g Evgenidion Hospital   (Greece)

^h Institute of Public Health   (Spain)

ⁱ LLANDOUGH HOSPITAL   (United Kingdom)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k MARMARA UNIVERSITY   (Turkey)

more..

Author keywords

Chronic obstructive pulmonary disease; Guidelines; Respiratory patients; Smoking cessation

Indexed keywords

AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; BRONCHODILATING AGENT; CARBON MONOXIDE; CLONIDINE; CORTICOSTEROID; INSULIN; NEUROLEPTIC AGENT; NICORETTE MICROTAB; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NIQUITIN CQ; NORTRIPTYLINE; PLACEBO; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TOBACCO SMOKE; UNCLASSIFIED DRUG; VARENICLINE;

ACUPUNCTURE; ANTICHOLINERGIC SYNDROME; ANXIETY; ARTICLE; BEHAVIOR THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; GROUP THERAPY; HEALTH CARE COST; HEALTH EDUCATION; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK PATIENT; HUMAN; HYPNOSIS; KINESIOTHERAPY; LOW LEVEL LASER THERAPY; LUNG CANCER; LUNG FUNCTION TEST; META ANALYSIS; MOTIVATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORAL MUCOSAL DISEASE; ORTHOSTATIC BLOOD PRESSURE; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT GUIDANCE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SEIZURE; SELF HELP; SELF MEDICATION; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SMOKING CESSATION; SPIROMETRY; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; THROAT IRRITATION; TOBACCO DEPENDENCE; TREATMENT CONTRAINDICATION; UNPLEASANT DREAM; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

HUMANS; PROGNOSIS; RESPIRATORY TRACT DISEASES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33846923351     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00060806     Document Type: Article

References (228)

1. Postma DS, Siafakas NM, eds. Management of Chronic Obstructive Pulmonary Disease. Eur Respir Mon 1998; 7.
2. Global Initiative for Chronic Obstructive Lung disease. NHLBI/WHO Workshop. US Dept of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute. NIH Publication No. 2701A. Bethesda, National Institutes of Health, 2001.
3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
4. Fletcher C, Peto R, Tinker C, Speizer FE, eds. The natural history of chronic bronchitis and emphysema. Oxford, Oxford University Press, 1976.
5. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.
6. Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement in hospital patients also given advice and support. Thorax 2002; 57: 715-718.
7. Borson S, Claypoole K, McDonald GJ. Depression and chronic obstructive pulmonary disease: treatment trials. Semin Clin Neuropsychiatry 1998; 3: 115-130.
8. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
9. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking cessation: clinical practice guidelines No. 18. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 96-0692. Rockville, US Dept of Health and Human Services, 1996.
10. Fiore M, Bailey W, Cohen S, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville, US Dept of Health and Human Services, 2000.
11. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000; 283: 3244-3254.
12. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932-941.
13. American College of Chest Physicians, American Thoracic Society, European Respiratory Society, Asian Pacific Society of Respirology, Canadian Thoracic Society, International Union Against Tuberculosis and Lung Disease. Smoking and health: the physician's responsibility. A statement by the Health and Smoking Committee. Pneumologie 1996; 50: 270-274.
14. Hughes JR, Fiester S, Goldstein MG, Resnick MP, Rock N, Ziedonis D. The American Psychiatric Association Practice Guidelines for the treatment of patients with nicotine dependence. Am J Psychiatry 1996; 153: Suppl. 10, S1-S31.
15. Haustein KO. Tobacco or Health? Berlin, Springer-Verlag, 2001; pp. 34-43.
16. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT. The genetic determinants of smoking. Chest 2003; 123: 1730-1739.
17. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2: 19-37.
18. US Department of Health and Human Services. Nicotine addiction. A report of the Surgeon General. Rockville, US Dept of Health and Human Services, 1998.
19. World Health Organization. International Classification of Diseases, 10th Edn. Geneva, World Health Organization, 1992.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Edn. Washington, American Psychiatric Association, 1994.
21. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 1991; 48: 52-59.
22. Shiffman S, West RJ, Gilbert DG. SRNT Work Group on the Assessment of Craving and Withdrawal in Clinical trials. Nicotine Tob Res 2004; 6: 599-614.
23. The World Bank. Curbing the Epidemic: Governments and the Economics of Tobacco Control. Washington, The World Bank, 1999. Available at www1.worldbank.org/tobacco/reports.asp. Date last accessed: March 15, 2005. Date last updated: 2001.
24. Tobacco Policy in the European Union: ASH Fact Sheet No. 20. www.ash.org.uk/html/factsheets/html/fact20.html. Date last accessed: November 28, 2005. Date last updated: May 2006.
25. Doxa. Indagine sul fumo in Italia 2004. www.doxa.it/italiano/inchieste/ fumo2004_ita.pdf. Date last accessed: March 15, 2005. Date last updated: April 2004.
26. Murin S, Bilello KS, Matthay R. Other smoking-affected pulmonary diseases. Clin Chest Med 2000; 21: 121-137.
27. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General, 2004. www.cdc.gov/tobacco/sgr/ sgr_2004/index.htm. Date last accessed: November 28, 2006. Date last updated: February 15, 2006.
28. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr., Doll R. Mortality from smoking worldwide. Br Med Bull 1996; 52: 12-21.
29. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-852.
30. Rodu B, Cole P. The burden of mortality from smoking: comparing Sweden with other countries in the European Union. Eur J Epidemiol 2004; 19: 129-131.
31. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1529-1533.
32. Lung cancer. In: European Respiratory Society/European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. Sheffield, ERS Journals, 2003; pp. 44-54.
33. La Vecchia C, Franceschi S, Levi F. Epidemiological research on cancer with a focus on Europe. Eur J Cancer Prev 2003; 12: 5-14.
34. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123: Suppl. 1, 21S-49S.
35. Flanders WD, Lally CA, Zhu BP, Henley SJ, Thun MJ. Lung cancer mortality in relation to age, duration of smoking, and daily cigarette consumption: results from Cancer Prevention Study II. Cancer Res 2003; 63: 6556-6562.
36. Simonato L, Agudo A, Ahrens W, et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 2001; 91: 876-887.
37. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
38. Chronic obstructive pulmonary disease. In: European Respiratory Society/ European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. Sheffield, ERS Journals, 2003; pp. 34-43.
39. Burney P, Suissa S, Soriano JB, et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J 2003; 22: Suppl. 42, 1s-44s.
40. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213.
41. Viegi G, Pedreschi M, Baldacci S, et al. Prevalence rates of respiratory symptoms and diseases in general population samples of North and Central Italy. Int J Tuberc Lung Dis 1999; 3: 1034-1042.
42. Lundback B, Lindberg A, Lindstrom M, et al. Obstructive lung disease in Northern Sweden studies. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122.
43. de Marco R, Accordini S, Cerveri I, et al., for the European Community Respiratory Health Survey (ECRHS) Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.
44. Jimenez-Ruiz CA, Masa F, Miravittles M, et al. Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.
45. Watson L., Boezen HM., Postma DS. Differences between males and females in the natural history of asthma and COPD. In: Buist S, Mapp CE, eds. Respiratory Diseases in Women. Eur Respir Mon 2003; 25: 50-73.
46. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68: 4-19.
47. Calverley PMA, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-1061.
48. Willemse BWM, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476.
49. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, for the Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005; 142: 233-239.
50. Cerveri I, Accordini S, Corsico A, et al., for the ISAYA Study Group. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22: 413-417.
51. Carrozzi L, Rijcken B, Burney P, et al. Family history for chronic lung diseases and epidemiological determinants of COPD in three European countries. Eur Respir Rev 2001; 11: 49-54.
52. Eagan TML, Gulsvik A, Eide GE, Bakke PS. Remission of respiratory symptoms by smoking and occupational exposure in a cohort study. Eur Respir J 2004; 23: 589-594.
53. Kerstjens HAM, Rijcken B, Schouten JP, Postma DS. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827.
54. Gold DR, Wang X, Wypij D, Speizer FE, Ware JH, Dockery DW. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937.
55. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows B. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991; 144: 17-22.
56. Xu X, Weiss ST, Rijcken B, Schouten JP. Smoking, changes in smoking habits, and rate of decline in FEV1: new insight into gender differences. Eur Respir J 1994; 7: 1056-1061.
57. Downs SH, Brandli O, Zellweger JP, et al. Accelerated decline in lung function in smoking women with airway obstruction: SAPALDIA 2 cohort study. Respir Res 2005; 6: 45.
58. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679.
59. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390.
60. Sherrill DL, Enright P, Cline M, Burrows B, Lebowitz MD. Rates of decline in lung function among subjects who restart cigarette smoking. Chest 1996; 109: 1001-1005.
61. Murray RP, Anthonisen NR, Connett JE, et al. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol 1998; 51: 1317-1326.
62. Bolliger CT, Zellweger JP, Danielsson T, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res 2002; 4: 433-439.
63. Viegi G, Paoletti P, Carrozzi L, et al. CO diffusing capacity in a general population sample: relationships with cigarette smoking and airflow obstruction. Respiration 1993; 60: 155-161.
64. Viegi G, Sherrill DL, Carrozzi L, et al. An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern Italy. Chest 2001; 120: 74-80.
65. Viegi G, Matteelli G, Annesi I. Epidemiology of asthma. In: Chung F, Fabbri LM, eds. Asthma. Eur Respir Mon 2003; 23: 1-25.
66. Ulrik CS, Lange P. Cigarette smoking and asthma. Monaldi Arch Chest Dis 2001; 56: 349-353.
67. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-833.
68. Doll R. Risk from tobacco and potentials for health gain. Int J Tuberc Lung Dis 1999; 3: 90-99.
69. Tønnesen P, Pisinger C, Hvidberg S, et al. Effects of smoking cessation and reduction in asthmatics. Nicotine Tob Res 2005; 7: 139-148.
70. Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000; 94: 954-963.
71. Almirall J, Gonzalez CA, Balanzo X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375-379.
72. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342: 681-689.
73. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-2216.
74. Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43 000 adult male deaths and 35 000 controls. Lancet 2003; 362: 507-515.
75. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA, Collaborating Centers. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248.
76. Chiyo M, Sekine Y, Iwata T, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 2003; 126: 1141-1146.
77. Henry M, Arnold T, Harvey J, on behalf of the BTS Pleural Disease Group, a subgroup of the BTS Standards of Care Committee. BTS guidelines for the management of spontaneous pneumothorax. Thorax 2003; 58: Suppl. II, 39-52.
78. Rollnick S, Mason P, Butler C. Health behaviour change: a guide for practitioners. London, Churchill Livingstone, 1999.
79. Fagerström KO. Time to first cigarette; the best single indicator of tobacco dependence. Monaldi Arch Chest Dis 2003; 59: 95-98.
80. Etter JF, Duc TV, Perneger TV. Saliva cotinine levels in smokers and non-smokers. Am J Epidem 2000; 151: 251-258.
81. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119-1127.
82. Fagerström KO, Schneider N. Measuring nicotine dependence: A review of the Fagerström Tolerance Questionnaire. J Behav Med 1989; 12: 159-182.
83. Breslau N, Johnson EO. Predicting smoking cessation and major depression in nicotine dependent smokers. Am J Pub Health 1999; 90: 1122-1127.
84. Batra A, Gelfort G, Bartels M. The dopamine D2 receptor (DRD2) gene - a genetic risk factor in heavy smoking? Addict Biol 2000; 5: 431-438.
85. Etter JF, LeHouezec J, Perneger TV. A self-administered questionnaire to measure addiction to cigarettes. The Cigarette Dependence Scale. Neuropsychopharmacology 2003; 28: 359-370.
86. Javors MA, Hatch JP, Lamb R. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 2005; 100: 159-167.
87. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.
88. Petty TL, Doherty DE. National Lung Health Education Program. The National Lung Health Education Program: roots, mission, future directions. Respir Care 2004; 49: 678-683.
89. Enright PL, Kaminsky DA. Strategies for screening for chronic obstructive pulmonary disease. Respir Care 2003; 48: 1194-1201.
90. Clotet J, Gomez-Arbones X, Ciria C, Aldalad JM. Spirometry is a good method for detecting and monitoring chronic obstructive pulmonary disease in high-risk smokers in primary care. Arch Bronconeumol 2004; 40: 155-159.
91. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Brit J Gen Pract 2004; 54: 201-206.
92. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
93. Bize R, Burnand B, Mueller Y, Cornuz J. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2005; 4: CD0004705.
94. Hughes JR. Comorbidity and smoking. Nicotine Tob Res 1999; 1: Suppl. 2, S149-S152.
95. Dierker LC, Avenevoli S, Stolar M, Merikangas KR. Smoking and depression: an examination of mechanisms of comorbidity. Am J Psychiatry 2002; 159: 947-953.
96. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the source of major depression: a follow up study. Lancet 2001; 357: 1929-1932.
97. Wagena E, Kant I, Huibers MJ, et al. Psychological distress and depressed mood in employees with asthma, chronic bronchitis or emphysema: a population-based observational study on prevalence and the relationship with smoking cigarettes. Eur J Epidemiol 2004; 19: 147-153.
98. Arrol B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003; 327: 1144-1146.
99. Watkins C, Daniels L, Jack C, Dickinson H, van der Broek M. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. BMJ 2001; 323: 1159.
100. Centers for Disease Control and Prevention. Smoking cessation during previous years among adults in United States 1990 and 1991. MMWR 1993; 42: 504-507.
101. US Dept of Health and Human Services. The health consequences of smoking: Chronic obstructive lung disease. A report of the Surgeon General. Rockville, US Dept of Health and Human Services, 1984.
102. van Manen JG, Bindels PJ, Dekker FW. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412-416.
103. Wagena EJ, Kant I, van Amelsvoort LG, Wouters EF, van Schaychk CP, Swaen GM. Risk of depression and anxiety in employees with chronic bronchitis: the modifying effect of cigarette smoking. Psychosom Med 2004; 5: 729-734.
104. Breslau N, Peterson EL, Schultz LR. Major depression and stages of smoking. A longitudinal investigation. Arch Gen Psychiatry 1998; 55: 161-166.
105. Covey LS, Glassaman AH, Stetner F. Cigarette smoking and major depression. J Addict Dis 1998; 17: 35-46.
106. West R, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989; 19: 981-985.
107. Shiffman S, Hickcox M, Paty J, Gnys M, Kassel J, Richards T. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996; 64: 993-1002.
108. Kim HF, Kunik ME, Molinari VA. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000; 41: 465-471.
109. de Voogd JN, Elzen HA. Psychological state and personality traits of patients in a pulmonary rehabilitation program. Eur Respir J 2001; 18: Suppl. 33, 54s.
110. Dudley DL, Wermuth C, Hague W. Psychological aspects of care in the chronic obstructive pulmonary disease patient. Heart Lung 1973; 2: 339-345.
111. Gorecka D, Bednarek M, Nowinski A, Plywaczewski R, Zielinski J, Bielen P. Nicotine dependence in smokers at risk for COPD. Eur Respir J 2002; 20: Suppl. 38, 134s.
112. Miloskovic V, Lazic Z. Lung function and level of the smoker's nicotine dependence. Eur Respir J 2001; 18: Suppl. 33, S115-S116.
113. Kunze U, Schoberberger R, Schmeiser-Rieder A, Fagerström K. Preventive oncology and nicotine addiction. In: Antypas G, ed. International Proceedings Division, 2nd International Congress on Lung Cancer. Bologna, Monduzzi Editore, 1996; pp. 551-554.
114. Mikami I, Akechi T, Kugaya A, et al. Screening for nicotine dependence among smoking-related cancer patients. Japan J Cancer Res 1999; 90: 1071-1075.
115. Jimenez-Ruiz CA, Miravitlles M, Sobradillo V, et al. Can cumulative tobacco consumption, FTND score, and carbon monoxide concentrations in expired air be predictors of chronic obstructive pulmonary disease? Nic Tob Res 2004; 6: 649-653.
116. Medici TC, Unger S, Ruegger M. Smoking pattern of smokers with and without tobacco-related lung diseases. Amer Rev Resp Dis 1985; 131: 385-388.
117. Pauwels RA, Buist AS, Calverley PM. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
118. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of COPD. Eur Respir J 1995; 8: 1398-1420.
119. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 961-966.
120. Filozof C, Fernadez Pinilla MC, Fernadez-Cruz A. Smoking cessation and weight gain. Obes Rev 2004; 5: 95-103.
121. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev 2005; 3: CD001118.
122. Borland R, Balmford J, Hunt D. The effectiveness of personally tailored computer generated advice letters for smoking cessation. Addiction 2004; 99: 369-377.
123. Quist-Paulsen P, Gallefos F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 2003; 327: 1254-1257.
124. Aveyard P, Griffin C, Lawrence T, Cheng KK. A controlled trial of an expert system and self-help manual intervention based on the stages of change versus standard self-help materials in smoking cessation. Addiction 2003; 98: 345-354.
125. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD000165.
126. Rice V, Stead LF. Nursing interventions for smoking cessation. Cochrane Database Syst Rev 2004; 1: CD001188.
127. British Thoracic Society. Comparison of four methods for smoking cessation in patients with smoking related disorders. BMJ 1983; 286: 595-597.
128. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2: CD001292.
129. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005; 2: CD001007.
130. Lichtenstein E, Glasgow RE, Lando HA, Ossip-Klein DJ, Boles SM. Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence. Health Educ Res 1996; 11: 243-257.
131. Stead LF, Lancaster T, Perera R. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006; 3: CD002850.
132. Borland R, Segan CJ, Livingston PM, Owen N. The effectiveness of callback counselling for smoking cessation: a randomised trial. Addiction 2001; 96: 881-889.
133. Macleod ZR, Charles MA, Arnaldi VC, Adams IM. Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial. Med J Aust 2003; 179: 349-352.
134. Hajek P, Stead LF. Aversive smoking for smoking cessation. Cochrane Database Syst Rev 2001; 3: CD000546.
135. Ussher M, Nunciata P, Cropley M, West R. Effect of a short bout of exercise on tobacco withdrawal symptoms and desire to smoke. Psychopharmacology (Berl) 2001; 158: 66-72.
136. Bock BC, Marcus BH, King TK, Borrelli B, Roberts MR. Exercise effects on withdrawal and mood among women attempting smoking cessation. Addict Behav 1999; 24: 399-410.
137. Steptoe A, Edwards S, Moses J, Mathews A. The effects of exercise training on mood and perceived coping ability in anxious adults from the general population. J Psychosom Res 1989; 33: 537-547.
138. McAuley E, Mihalko SL, Bane SM. Exercise and self-esteem in middle-aged adults: multidimensional relationships and physical fitness and self-efficacy influences. J Behav Med 1997; 20: 67-83.
139. Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst Rev 2005; 1: CD002295.
140. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
141. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; 4: CD00031.
142. Crowley TJ, Macdonald MJ, Walter MI. Behavioural anti-smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology 1995; 119: 193-204.
143. Pederson LL, Wanklin JM, Lefcoe NM. The effect of counselling on smoking cessation among patients hospitalised with chronic obstructive pulmonary disease: a randomised clinical trial. Int J Addiction 1991; 26: 107-119.
144. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815.
145. Research Committee of the British Thoracic Society. Smoking cessation in patients: two further studies by the British Thoracic Society. Thorax 1990; 45: 835-840.
146. Tønnesen P, Mikkelsen KL. Routine smoking cessation with four nicotine regiments in a lung clinic. Eur Respir J 2000; 16: 717-722.
147. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax 2000; 55: 987-999.
148. World Health Organisation. European partnership to reduce tobacco dependence: WHO evidence based recommendations on the treatment of tobacco dependence. Geneva, WHO, 2001.
149. National Institute for Health and Clinical Excellence. Smoking cessation - bupropion and nicotine replacement therapy. National Institute for Health and Clinical Excellence Technology appraisal TA39. www.nice.org.uk/page.aspx?o=TA39. Date last accessed: May 2006. Date last updated: March 2002.
150. Andersson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence. Chest 2002; 121: 932-941.
151. Wagena E, Zeegers M, Van Schayck C, Wouters E. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26: 381-403.
152. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: The Lung Health Study. JAMA 1994; 272: 1497-1505.
153. Sachs DPL, Benowitz NL, Silver KJ. Effective use of nicotine polacrilex (Nicorette) in patients with chronic obstructive pulmonary disease. In: Aoki M, Hisamichi S, Tominaga S, eds. Smoking and health. Amsterdam, Elsevier, 1987; pp. 793-795.
154. Glover ED, Glover PN, Abrons HL, et al. Smoking cessation among COPD and chronic bronchitis patients using the nicotine nasal spray. Am J Health Behav 1997; 21: 310-317.
155. Tønnesen P. Smoking cessation. In: Pauwels RA, Postma DS, Weiss ST, eds. Long-term intervention in chronic obstructive pulmonary disease. Lung Biology in Health and Disease, vol. 191. New York, Marcel Dekker, 2005; pp. 315-352.
156. Campell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. Respir Med 1991; 85: 155-157.
157. Campbell IA, Prescott RJ, Teder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. Respir Med 1996; 90: 47-51.
158. Miller NH, Smith PM, DeBusk RF, Sobel DS, Taylor CB. Smoking cessation in hospitalized patients: results of a randomized trial. Arch Intern Med 1997; 157: 409-415.
159. Lewis SF, Piasecki TM, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. Prev Med 1998; 27: 296-303.
160. Tønnesen P, Mikkelsen KL, Markholst C, et al. Nurse-conducted smoking cessation with minimal intervention in a lung clinic: a randomized controlled study. Eur Respir J 1996; 9: 2351-2355.
161. Tønnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD, using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 314-316.
162. Gratziou C, Francis K, Maragianni A, et al. Bupropion treatment and cognitive behavioral therapy in smoking cessation program. Eur Respir J 2001; 18: Suppl. 33, 12s.
163. Richmond R, Zwar N. Review of bupropion for smoking cessation. Drug and Alcohol Review 2003; 22: 203-220.
164. Tønnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counseling in smoking cessation: An open, randomized, controlled trial with a 22 month follow-up. Addict Behav 1988; 13: 17-27.
165. Tønnessen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial. Eur Respir J 1999; 13: 238-246.
166. Shiffman S, Dressler C, Hajek P, Gilburt S, Targett D, Strahs K. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267-1276.
167. Ferry LH, Burchette RJ. Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Disord 1994; 13: 249.
168. Dalsgareth O, Hansen N, Soes-Petersen U, et al. A multicentre, randomised, double blind, placebo controlled, 6-month trial of bupropion hydrochloride sustained release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 2004; 6: 55-61.
169. Garcia-Rio F, Serrano S, Mediano O, Alonso A, Vilamor J. Safety profile of bupropion for COPD. Lancet 2001; 358: 1009-1010.
170. Tonstad S, Farsang D, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24: 946-955.
171. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med 2001; 135: 423-433.
172. Sampablo I, Lores L, Coll-Klein F, Jimenez C, Rebasa P. Predictive factors in smoking cessation with combined therapy with bupropion and nicotine patches. Monaldi Arch Chest Dis 2003; 59: 171-176.
173. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
174. Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54: 670-679.
175. Hilleman DE, Mohiuddin SM, Delcore MG, Lucas BD Jr. Randomized controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 1993; 27: 1025-1028.
176. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
177. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296: 56-63.
178. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006; 296: 64-71.
179. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 2005; 81: 387-395.
180. Anthenelli RM, Despres JP. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit). American College of Cardiology 53rd Annual Scientific Session. New Orleans, American College of Cardiology, 2004.
181. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1364-1389.
182. White A, Resch K, Ernst E. A metanalysis of acupuncture techniques for smoking cessation. Tob Control 1999; 8: 393-397.
183. Yiming C, Changxin Z, Ung WS, Lei Z, Kean LS. Laser acupuncture for adolescent smokers - a randomised, double-blind controlled trial. Am J Chin Med 2000; 28: 443-449.
184. Abbot NC, Stead LF, White AR, Barnes J, Ernst E. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev 1998; 2: CD001008.
185. Bolliger CT, Zellweger JP, Danielsson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000; 321: 329-333.
186. Wennike P, Danielsson T, Landfeldt T, Westin Å, Tønnesen P. Smoking reduction promotes smoking cessation: Results from a double blind, randomised, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction 2003; 98: 1395-1402.
187. Hughes JR, Cummings KM, Hyland A. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction 1999; 94: 109-114.
188. Gotfredsen N, Prescott E, Osler M, Vestbo J. Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Prev Med 2001; 33: 46-52.
189. Tønnesen P, Danielsson T. Cutting down smoking then stopping with nicotine replacement therapy: an innovative approach to smoking cessation. Thorax 2005; 60: Suppl. II, ii36.
190. Hughes JR, Carpenter MJ. Can medications or behavioral treatment reduce smoking in smokers not trying to quit? A review. Proceedings of the Society for Research on Nicotine and Tobacco 2005: 8.
191. Hughes JR. Smoking reduction: efficacy and implementation. Addiction 2000; 95: Suppl. 1, S3-S37.
192. Bates C, McNeill A, Jarvis M, Gray N. The future of tobacco product regulation and labelling in Europe: Implications for the forthcoming European Union directive. Tob Control 1999; 8: 225-235.
193. Fagerström KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control 2000; 9: 327-333.
194. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. Tob Control 2005; 14: 161-165.
195. Glynn TJ, Manley MW. How to help your patients to stop smoking: A National Cancer Institute Manual for Physicians. NIH Publication No. 93-3064. Bethesda, National Institutes of Health, 1993.
196. Prochaska JO, Goldstein MG. Process of smoking cessation. Implications for clinicians. Clin Chest Med 1991; 12: 727-735.
197. Jarvis MJ, Russell MA, Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. BMJ 1980; 281: 484-485.
198. Heffner JE. The overarching challenge. Chest 2000; 118: Suppl. 2, 1S-3S.
199. Smith WR. Evidence for the effectiveness of techniques to change physician behavior. Chest 2000; 118: Suppl. 2, 8S-17S.
200. Heffner JE, Alberts WM, Irwin R, Wunderink R. Translating guidelines into clinical practice. Recommendations to the American College of Chest Physicians. Chest 2000; 118: Suppl. 2, 70S-73S.
201. Nardini S, Bertoletti R, Rastelli V, Donner CF. The influence of personal tobacco smoking on the clinical practice of Italian chest physicians. Eur Respir J 1998; 12: 1450-1453.
202. European Smoke-Free Hospital Network. http://ensh.aphp.fr. Date last accessed: November 28, 2006. Date last modified: November 23, 2006.
203. Johnson E, Dominici F, Griswold M, Zeger SL. Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey. J Econometrics 2003; 112: 135-151.
204. Barendregt JJ, Bonneux L, van der Maas J. The health care costs of smoking. N Engl J Med 1997; 337: 1052-1057.
205. Ruff LK, Volmer T, Nowak D, Meyer A. The economic impact of smoking in Germany. Eur Respir J 2000; 16: 385-390.
206. Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax 1998; 53: Suppl. 5, S1-S38.
207. Godfrey C. The economic and social costs of lung cancer and the economics of smoking prevention. Monaldi Arch Chest Dis 2001; 56: 458-461.
208. World Health Organization. Economic Consequences of Smoking (ECOS) model. WHO European Partnership Project to Reduce Tobacco Dependence. Copenhagen-Geneva, World Health Organization, 1999.
209. Lazzaro C. Health and Economic Consequences of Smoking (ECOS) model. WHO European Partnership Project to Reduce Tobacco Dependence. Appendix 1. Copenhagen-Geneva, World Health Organization, 1999.
210. Parrott S, Godfrey C, Raw M. Costs of employee smoking in the workplace in Scotland. Tob Control 2000; 9: 187-192.
211. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd Edn. Oxford, Oxford University Press, 1997; pp. 109-112.
212. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, Oxford University Press, 1996.
213. Maynard A. Developing the health care market. Econ J 1991; 101: 1277-1286.
214. Schulmann KA, Loma AL, Glick HA, Eisenberg J. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Int Med 1991; 114: 798-802.
215. Rutten-Van Mölken MPMH, Van Doorslaer EKA, Rutten FFH. Economic appraisal of asthma and COPD care: a literature review 1980-1981. Soc Sci Med 1992; 35: 161-175.
216. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 1997; 278: 1759-1766.
217. Department of Health. Independent inquiry into inequalities in health. London, Stationery Office, 1998.
218. NHS Centre for Reviews & Dissemination. A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. York, University of York, 2002.
219. Invernizzi G, Nardini S, Bettoncelli G, et al. L'intervento del medico di medicina generale nel controllo del fumo. Rassegna di Patologia dell'Apparato Respiratorio 2002; 17: 55-70.
220. Baker D, Illsley R. Inequalities in health. Studies in inequality in health need careful interpretation. BMJ 1998; 317: 1659.
221. Whitfield L. Social policies "must focus on inequalities". Health Service Journal 1998; 108: 8.
222. Harris JE, Chan SW. The continuum-of-addiction: cigarette smoking in relation to price among Americans aged 15-29. Health Econ 1999; 8: 81-86.
223. Becker GS, Murphy KM. A theory of rational addiction. Journal of Political Economy 1988; 96: 675-700.
224. Becker GS, Grossman M, Murphy KM. An empirical analysis of cigarette addiction. American Econ Rev 1994; 84: 396-418.
225. Chaloupka FJ, Tauras J, Grossman M. Economic models of addiction and applications to cigarette smoking and other substance abuse. Chicago, University of Illinois 1999; pp. 1-27.
226. Chaloupka FJ. Tobacco taxation. www.impacteen.org/generalarea-PDFs/ NCSLSEATTLE111601.pdf. Date last accessed: September 22, 2006.
227. Chaloupka FJ. Price, tobacco control policies and youth and young adult tobacco use. www.iinpacteen.org/generalareaPDFs/TUPT1082401.pdf. Date last accessed: September 22, 2006.
228. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tobacco Control 2006; 15: 152-159.